Leerink Partnrs Increases Earnings Estimates for 908 Devices

908 Devices Inc. (NASDAQ:MASS) – Analysts at Leerink Partnrs raised their FY2025 earnings per share estimates for 908 Devices in a research report issued on Monday, November 10th. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.61) per share for the year, up from their prior forecast of ($0.62). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.32) EPS and FY2027 earnings at ($0.29) EPS.

Several other analysts have also recently issued reports on the company. Wall Street Zen upgraded 908 Devices from a “sell” rating to a “hold” rating in a research note on Monday, September 15th. Leerink Partners upgraded shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

908 Devices Stock Performance

Shares of MASS opened at $5.90 on Thursday. 908 Devices has a 1 year low of $1.81 and a 1 year high of $9.34. The company’s 50-day simple moving average is $7.60 and its 200-day simple moving average is $6.77. The stock has a market capitalization of $213.52 million, a PE ratio of -53.64 and a beta of 0.45.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). 908 Devices had a negative net margin of 7.17% and a negative return on equity of 22.31%. The firm had revenue of $4.80 million during the quarter, compared to analysts’ expectations of $13.58 million. 908 Devices has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On 908 Devices

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cresset Asset Management LLC boosted its stake in shares of 908 Devices by 37.1% in the third quarter. Cresset Asset Management LLC now owns 16,100 shares of the company’s stock valued at $141,000 after buying an additional 4,355 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in 908 Devices by 125.9% in the third quarter. First Eagle Investment Management LLC now owns 603,962 shares of the company’s stock valued at $5,291,000 after acquiring an additional 336,584 shares during the period. AXQ Capital LP purchased a new stake in shares of 908 Devices during the 3rd quarter worth $114,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of 908 Devices during the 3rd quarter worth $627,000. Finally, Essex Investment Management Co. LLC grew its stake in shares of 908 Devices by 3.5% during the 3rd quarter. Essex Investment Management Co. LLC now owns 493,949 shares of the company’s stock worth $4,327,000 after purchasing an additional 16,607 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $7.07, for a total transaction of $35,350.00. Following the completion of the transaction, the chief financial officer directly owned 97,930 shares of the company’s stock, valued at $692,365.10. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 10,000 shares of company stock worth $80,593 in the last quarter. Insiders own 23.70% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.